Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma

被引：5
|
作者：
Majem, M. [1 ]
Felip, E. [2 ]
Doger, B. [3 ]
Akay, M. [4 ]
Carcereny, E. [5 ]
Clay, T. [6 ]
Krebs, M. G. [7 ]
Peguero, J. [8 ]
Triebel, F. [9 ]
机构：
[1] Hosp Santa Creu & Sant Pau, Med Oncol Dept, Barcelona, Spain
[2] Vall dHebron Univ Hosp, Med Oncol, Barcelona, Spain
[3] Fdn Jimenez Diaz, START Madrid FJD, Madrid, Spain
[4] Univ Coll London Hosp, Oncol Dept, London, England
[5] Hosp Badalona Germans Trias & Pujol, Inst Catala Oncol Badalona, Oncol Dept, Badalona, Spain
[6] St John God Subiaco Hosp, Oncol Dept, Perth, WA, Australia
[7] Christie NHS Fdn Trust, Div Canc Sci, Manchester, Lancs, England
[8] Oncol Consultants, Oncol Dept, Houston, TX USA
[9] Immutep SAS Immutep, Immunol, Orsay, France
来源：
ANNALS OF ONCOLOGY | 2020年 / 31卷
关键词：
D O I：
10.1016/j.annonc.2020.08.1580
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1266P
引用
收藏
页码：S818 / S818
页数：1
相关论文
共 50 条
  • [21] INSIGHT 003 evaluating feasibility of eftilagimod alpha (soluble LAG-3) combined with first-line chemo-immunotherapy in metastatic non-small cell lung cancer (NSCLC) adenocarcinomas
    Atmaca, A.
    Mueller, D. W.
    Habibzada, T.
    Schaaf, M.
    Klagges, J.
    Eickhoff, R.
    Jaeger, E.
    Al-Batran, S-E.
    Goetze, T. O.
    ANNALS OF ONCOLOGY, 2023, 34 : S632 - S632
  • [22] First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy
    Zhou, Yixin
    Lin, Zuan
    Zhang, Xuanye
    Chen, Chen
    Zhao, Hongyun
    Hong, Shaodong
    Zhang, Li
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [23] Beyond PD-L1: Assessment of LAG-3 and other predictive biomarkers in non-small cell lung carcinoma
    Hung, Yin P.
    Mino-Kenudson, Mari
    CANCER CYTOPATHOLOGY, 2023, 131 (03) : 151 - 153
  • [24] Outcomes to first-line pembrolizumab in patients with non-small cell lung cancer and a PD-L1 tumor proportion score ≥90%.
    Aguilar, Elizabeth Jimenez
    Ricciuti, Biagio
    Gainor, Justin F.
    Nishino, Mizuki
    Adeni, Anika E.
    Subegdjo, Safiya
    Khosrowjerdi, Sara
    Peterson, Rachel
    Digumarthy, Subba
    Liu, Corinne
    Sauter, Jennifer L.
    Rizvi, Hira
    Arbour, Kathryn Cecilia
    Carter, Brett W.
    Heymach, John
    Altan, Mehmet
    Hellmann, Matthew David
    Awad, Mark M.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [25] Phase 2 study of first-line pembrolizumab in elderly patients with non-small cell lung cancer expressing high PD-L1.
    Hamai, Kosuke
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [26] Real-world first-line treatment with pembrolizumab for non-small cell lung carcinoma with high PD-L1 expression: Updated analysis
    Ikezawa, Yasuyuki
    Morita, Ryo
    Mizugaki, Hidenori
    Tateishi, Kazunari
    Yokoo, Keiki
    Sumi, Toshiyuki
    Kikuchi, Hajime
    Kitamura, Yasuo
    Nakamura, Atsushi
    Kobayashi, Maki
    Aso, Mari
    Kimura, Nozomu
    Yoshiike, Fumiaki
    Megumi, Furuta
    Tanaka, Hisashi
    Sekikawa, Motoki
    Hachiya, Tsutomu
    Nakamura, Keiichi
    Hommura, Fumihiro
    Sukoh, Noriaki
    Ito, Kenichiro
    Kikuchi, Takashi
    Agatsuma, Toshihiko
    Yokouchi, Hiroshi
    CANCER MEDICINE, 2024, 13 (14):
  • [27] First-line pembrolizumab for non-small cell lung cancer patients with PD-L1 ≥50% in a multicenter real-life cohort: The PEMBREIZH study
    Amrane, Karim
    Geier, Margaux
    Corre, Romain
    Lena, Herve
    Leveiller, Guillaume
    Gadby, Florence
    Lamy, Regine
    Bizec, Jean-Louis
    Goarant, Eric
    Robinet, Gilles
    Gouva, Sylvie
    Quere, Gilles
    Abgral, Ronan
    Schick, Ulrike
    Bernier, Cyril
    Chouaid, Christos
    Descourt, Renaud
    CANCER MEDICINE, 2020, 9 (07): : 2309 - 2316
  • [28] Phase 2 study of first-line pembrolizumab monotherapy in elderly patients with non-small-cell lung cancer expressing high PD-L1
    Masuda, Takeshi
    Fujitaka, Kazunori
    Suzuki, Tomoko
    Hamai, Kosuke
    Matsumoto, Naoko
    Matsumura, Mirai
    Isoyama, Shoko
    Ueno, Sayaka
    Mito, Mineyo
    Yamaguchi, Kakuhiro
    Sakamoto, Shinjiro
    Kawano, Reo
    Masuda, Ken
    Nishino, Ryohei
    Ishikawa, Nobuhisa
    Yamasaki, Masahiro
    Hattori, Noboru
    THORACIC CANCER, 2022, 13 (11) : 1611 - 1618
  • [29] Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial
    Hui, R.
    Garon, E. B.
    Goldman, J. W.
    Leighl, N. B.
    Hellmann, M. D.
    Patnaik, A.
    Gandhi, L.
    Eder, J. P.
    Ahn, M-J
    Horn, L.
    Felip, E.
    Carcereny, E.
    Rangwala, R.
    Lubiniecki, G. M.
    Zhang, J.
    Emancipator, K.
    Roach, C.
    Rizvi, N. A.
    ANNALS OF ONCOLOGY, 2017, 28 (04) : 874 - 881
  • [30] Real-World Efficacy of First-Line Pembrolizumab in Patients with Advanced PD-L1 High Non-Small Cell Lung Cancer in Argentina
    Kuzminin, A.
    Minatta, N.
    Bluthgen, M.
    Rizzo, M.
    Naveira, M.
    Wainsztein, V.
    Lupinacci, L.
    Rizzi, M.
    Faura, M.
    Perfetti, A.
    Recondo, G., Jr.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S589 - S590
12345